Capricor Therapeutics
Market Cap
US$66.2m
Last Updated
2020/05/30 04:47 UTC
Data Sources
Company Financials +
Executive Summary
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders.
Rewards
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has Capricor Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CAPR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-13.9%
CAPR
-0.5%
US Biotechs
2.7%
US Market
1 Year Return
48.3%
CAPR
26.8%
US Biotechs
9.1%
US Market
Return vs Industry: CAPR exceeded the US Biotechs industry which returned 26.8% over the past year.
Return vs Market: CAPR exceeded the US Market which returned 9.1% over the past year.
Shareholder returns
| CAPR | Industry | Market | |
|---|---|---|---|
| 7 Day | -13.9% | -0.5% | 2.7% |
| 30 Day | -33.7% | 3.6% | 4.5% |
| 90 Day | 293.2% | 14.2% | 2.3% |
| 1 Year | 48.3%48.3% | 28.0%26.8% | 11.5%9.1% |
| 3 Year | -43.8%-43.8% | 33.7%29.3% | 30.6%22.0% |
| 5 Year | -92.3%-92.3% | -3.1%-8.9% | 57.2%39.5% |
Price Volatility Vs. Market
How volatile is Capricor Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Introducing Capricor Therapeutics (NASDAQ:CAPR), The Stock That Tanked 93%1 month ago | Simply Wall St
Does Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Matter?1 month ago | Simply Wall St
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Deliver On Growth Plans?Valuation
Is Capricor Therapeutics undervalued compared to its fair value and its price relative to the market?
4.44x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CAPR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CAPR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAPR is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.7x).
Next Steps
Future Growth
How is Capricor Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
61.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAPR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CAPR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CAPR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CAPR's revenue (72.3% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: CAPR's revenue (72.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CAPR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Capricor Therapeutics performed over the past 5 years?
11.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CAPR is currently unprofitable.
Growing Profit Margin: CAPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CAPR is unprofitable, but has reduced losses over the past 5 years at a rate of 11.8% per year.
Accelerating Growth: Unable to compare CAPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: CAPR has a negative Return on Equity (-75.13%), as it is currently unprofitable.
Next Steps
Financial Health
How is Capricor Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CAPR's short term assets ($13.8M) exceed its short term liabilities ($1.3M).
Long Term Liabilities: CAPR's short term assets ($13.8M) exceed its long term liabilities ($3.4M).
Debt to Equity History and Analysis
Debt Level: CAPR is debt free.
Reducing Debt: CAPR has no debt compared to 5 years ago when its debt to equity ratio was 126%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAPR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CAPR has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 15% each year.
Next Steps
Dividend
What is Capricor Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CAPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CAPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Linda Marbán (56yo)
10.33yrs
Tenure
US$228,919
Compensation
Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be ...
CEO Compensation Analysis
Compensation vs Market: Linda's total compensation ($USD228.92K) is below average for companies of similar size in the US market ($USD589.04K).
Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | no data | US$185.84k | 0.14% $94.6k | |
| Co-Founder | 10.33yrs | US$228.92k | 2.32% $1.5m | |
| CFO & Corporate Treasurer | 2.33yrs | US$252.83k | 0.0014% $939.8 | |
| Executive VP | 8.17yrs | US$340.33k | 0.0078% $5.2k | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Vice President of Research & Development | 0.33yr | no data | no data | |
| Consultant | 1.5yrs | US$364.90k | no data | |
| Consultant | no data | no data | no data |
2.3yrs
Average Tenure
56yo
Average Age
Experienced Management: CAPR's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | no data | US$185.84k | 0.14% $94.6k | |
| Co-Founder | 10.33yrs | US$228.92k | 2.32% $1.5m | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.5yrs | US$14.12k | no data | |
| Independent Director | 6.5yrs | US$12.67k | no data | |
| Independent Director | 6.5yrs | US$24.24k | 0.21% $139.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.5yrs | US$11.95k | 0.70% $464.6k | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.5yrs
Average Tenure
67.5yo
Average Age
Experienced Board: CAPR's board of directors are considered experienced (6.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 311.4%.
Top Shareholders
Company Information
Capricor Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Capricor Therapeutics, Inc.
- Ticker: CAPR
- Exchange: NasdaqCM
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$66.185m
- Shares outstanding: 14.26m
- Website: https://www.capricor.com
Number of Employees
Location
- Capricor Therapeutics, Inc.
- 8840 Wilshire Boulevard
- 2nd Floor
- Beverly Hills
- California
- 90211
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CAPR | NasdaqCM (Nasdaq Capital Market) | Yes | New Common Stock | US | USD | Nov 2013 |
| 4LN2 | DB (Deutsche Boerse AG) | Yes | New Common Stock | DE | EUR | Nov 2013 |
Biography
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company’s development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/30 04:47 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.